Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,investments,changeToOperatingActivities,depreciation,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,IUGNF,32604608,4945099776,3566132,,-3031369,,-3031369,1504090,2055099,-3015124,-3015124,,-56218,,,,0,2055099,5070222,0,-16246,,-3031369,-3031369,30458449,4755348,63063057,1688148,67818405,101497239,668971,-53259316,988341,14825134,15593,32832479,3767007,14825134,116782,37147581,80000,3646131,1812415,0.0,-673401.0,-14435.0,4038725.0,4116644.0,1362862.0,27901.0,-2030363.0,55517.0,-63484.0,1001006.0,-1648.0,,,,,33380574,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,IMUGENE LIMITED,us_market,4,Other OTC,Imugene Limited,AUD,90953,157146,0.2525,7.769231,0.0325 - 0.3857,-0.10069999,-0.26108372,0.0325,0.3857,-0.002,0,0.013,0.23552333,0.04947667,0.2100712,0.20072503,0.08427496,0.41985276,1409353472,21.923077,15,America/New_York,EDT,-14400000,False,False,-2.829869,0.2761 - 0.285,0.2933,finmb_11113368,0.285,1630525675,-0.008300006,0.2761,0.285,0.2761,86237,2.16,,,0.3857,0.0325,0.2355,0.2007,90.95k,157.15k,4.95B,,3.81B,19.02%,2.42%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-200.70%,-202.66%,-10.74%,-18.40%,5.87M,0.00,73.10%,4.13M,-11.86M,-11.78M,-0.0020,,32.83M,0.01,40.47k,0.06,9.86,0.01,-10.85M,-8.11M,Value,2000,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",Sydney,61 3 9824 5254,NSW,1609372800,Australia,http://www.imugene.com,86400,37 Bligh Street,Biotechnology,Suite 1006 Level 10
t-1,IUGNF,32604608,4945099776,3566132,,-3031369,,-3031369,1504090,2055099,-3015124,-3015124,,-56218,,,,0,2055099,5070222,0,-16246,,-3031369,-3031369,30458449,4755348,63063057,1688148,67818405,101497239,668971,-53259316,988341,14825134,15593,32832479,3767007,14825134,116782,37147581,80000,3646131,1812415,0.0,-673401.0,-14435.0,4038725.0,4116644.0,1362862.0,27901.0,-2030363.0,55517.0,-63484.0,1001006.0,-1648.0,,,,,33380574,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,IMUGENE LIMITED,us_market,4,Other OTC,Imugene Limited,AUD,90953,157146,0.2525,7.769231,0.0325 - 0.3857,-0.10069999,-0.26108372,0.0325,0.3857,-0.002,0,0.013,0.23552333,0.04947667,0.2100712,0.20072503,0.08427496,0.41985276,1409353472,21.923077,15,America/New_York,EDT,-14400000,False,False,-2.829869,0.2761 - 0.285,0.2933,finmb_11113368,0.285,1630525675,-0.008300006,0.2761,0.285,0.2761,86237,2.16,,,0.3857,0.0325,0.2355,0.2007,90.95k,157.15k,4.95B,,3.81B,19.02%,2.42%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-200.70%,-202.66%,-10.74%,-18.40%,5.87M,0.00,73.10%,4.13M,-11.86M,-11.78M,-0.0020,,32.83M,0.01,40.47k,0.06,9.86,0.01,-10.85M,-8.11M,Value,2000,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",Sydney,61 3 9824 5254,NSW,1609372800,Australia,http://www.imugene.com,86400,37 Bligh Street,Biotechnology,Suite 1006 Level 10
t-2,IUGNF,29347894,4945099776,2565295,,-2858696,,-2858696,1246714,879597,-2932412,-2932412,,-1077,,,,0,879597,3812009,0,73717,,-2858696,-2858696,30458449,5398605,59806343,1438209,65204948,92797564,194059,-47310259,2490721,14319038,15593,30106755,2899482,14319038,155624,34494644,80638,4193830,1013039,-499970.0,83869.0,-13893.0,-14971.0,4116644.0,-3330124.0,-5037.0,-3393985.0,86593.0,-1077.0,-66201.0,-2405.0,-319.0,6422.0,41248.0,-16787.0,31595162,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,IMUGENE LIMITED,us_market,4,Other OTC,Imugene Limited,AUD,90953,157146,0.2525,7.769231,0.0325 - 0.3857,-0.10069999,-0.26108372,0.0325,0.3857,-0.002,0,0.013,0.23552333,0.04947667,0.2100712,0.20072503,0.08427496,0.41985276,1409353472,21.923077,15,America/New_York,EDT,-14400000,False,False,-2.829869,0.2761 - 0.285,0.2933,finmb_11113368,0.285,1630525675,-0.008300006,0.2761,0.285,0.2761,86237,2.16,,,0.3857,0.0325,0.2355,0.2007,90.95k,157.15k,4.95B,,3.81B,19.02%,2.42%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-200.70%,-202.66%,-10.74%,-18.40%,5.87M,0.00,73.10%,4.13M,-11.86M,-11.78M,-0.0020,,32.83M,0.01,40.47k,0.06,9.86,0.01,-10.85M,-8.11M,Value,2000,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",Sydney,61 3 9824 5254,NSW,1609372800,Australia,http://www.imugene.com,86400,37 Bligh Street,Biotechnology,Suite 1006 Level 10
t-3,IUGNF,29347894,4945099776,2565295,,-2858696,,-2858696,1246714,879597,-2932412,-2932412,,-1077,,,,0,879597,3812009,0,73717,,-2858696,-2858696,30458449,5398605,59806343,1438209,65204948,92797564,194059,-47310259,2490721,14319038,15593,30106755,2899482,14319038,155624,34494644,80638,4193830,1013039,-499970.0,83869.0,-13893.0,-14971.0,4116644.0,-3330124.0,-5037.0,-3393985.0,86593.0,-1077.0,-66201.0,-2405.0,-319.0,6422.0,41248.0,-16787.0,31595162,en-US,US,EQUITY,False,Delayed Quote,PRE,USD,PNK,IMUGENE LIMITED,us_market,4,Other OTC,Imugene Limited,AUD,90953,157146,0.2525,7.769231,0.0325 - 0.3857,-0.10069999,-0.26108372,0.0325,0.3857,-0.002,0,0.013,0.23552333,0.04947667,0.2100712,0.20072503,0.08427496,0.41985276,1409353472,21.923077,15,America/New_York,EDT,-14400000,False,False,-2.829869,0.2761 - 0.285,0.2933,finmb_11113368,0.285,1630525675,-0.008300006,0.2761,0.285,0.2761,86237,2.16,,,0.3857,0.0325,0.2355,0.2007,90.95k,157.15k,4.95B,,3.81B,19.02%,2.42%,,,,,,,,,,,0.00%,,,,,"Jun 29, 2020","Dec 30, 2020",-200.70%,-202.66%,-10.74%,-18.40%,5.87M,0.00,73.10%,4.13M,-11.86M,-11.78M,-0.0020,,32.83M,0.01,40.47k,0.06,9.86,0.01,-10.85M,-8.11M,Value,2000,Healthcare,"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",Sydney,61 3 9824 5254,NSW,1609372800,Australia,http://www.imugene.com,86400,37 Bligh Street,Biotechnology,Suite 1006 Level 10
